These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 23403069)
1. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Puntel M; A K M GM; Farrokhi C; Vanderveen N; Paran C; Appelhans A; Kroeger KM; Salem A; Lacayo L; Pechnick RN; Kelson KR; Kaur S; Kennedy S; Palmer D; Ng P; Liu C; Krasinkiewicz J; Lowenstein PR; Castro MG Toxicol Appl Pharmacol; 2013 May; 268(3):318-30. PubMed ID: 23403069 [TBL] [Abstract][Full Text] [Related]
2. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. Puntel M; Muhammad AK; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Bondale NS; Lerner J; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG J Virol; 2010 Jun; 84(12):6007-17. PubMed ID: 20375153 [TBL] [Abstract][Full Text] [Related]
3. Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Muhammad AK; Xiong W; Puntel M; Farrokhi C; Kroeger KM; Salem A; Lacayo L; Pechnick RN; Kelson KR; Palmer D; Ng P; Liu C; Lowenstein PR; Castro MG Hum Gene Ther Methods; 2012 Aug; 23(4):271-84. PubMed ID: 22950971 [TBL] [Abstract][Full Text] [Related]
4. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Muhammad AK; Puntel M; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Lawrence K; Bondale NS; Lerner J; Baker GJ; Foulad D; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG Clin Pharmacol Ther; 2010 Aug; 88(2):204-13. PubMed ID: 20164833 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. VanderVeen N; Paran C; Krasinkiewicz J; Zhao L; Palmer D; Hervey-Jumper S; Ng P; Lowenstein PR; Castro MG Hum Gene Ther Clin Dev; 2013 Sep; 24(3):116-26. PubMed ID: 24007469 [TBL] [Abstract][Full Text] [Related]
6. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Candolfi M; Pluhar GE; Kroeger K; Puntel M; Curtin J; Barcia C; Muhammad AK; Xiong W; Liu C; Mondkar S; Kuoy W; Kang T; McNeil EA; Freese AB; Ohlfest JR; Moore P; Palmer D; Ng P; Young JD; Lowenstein PR; Castro MG Neuro Oncol; 2007 Jul; 9(3):245-58. PubMed ID: 17522335 [TBL] [Abstract][Full Text] [Related]
8. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AK; Pechnick RN; Lowenstein PR; Castro MG Mol Ther; 2008 Apr; 16(4):682-90. PubMed ID: 18283279 [TBL] [Abstract][Full Text] [Related]
9. Adenoviral-mediated gene transfer into the canine brain in vivo. Candolfi M; Kroeger KM; Pluhar GE; Bergeron J; Puntel M; Curtin JF; McNiel EA; Freese AB; Ohlfest JR; Moore P; Lowenstein PR; Castro MG Neurosurgery; 2007 Jan; 60(1):167-77; discussion 178. PubMed ID: 17228266 [TBL] [Abstract][Full Text] [Related]
10. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Candolfi M; Yagiz K; Foulad D; Alzadeh GE; Tesarfreund M; Muhammad AK; Puntel M; Kroeger KM; Liu C; Lee S; Curtin JF; King GD; Lerner J; Sato K; Mineharu Y; Xiong W; Lowenstein PR; Castro MG Clin Cancer Res; 2009 Jul; 15(13):4401-14. PubMed ID: 19570774 [TBL] [Abstract][Full Text] [Related]
11. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Ali S; King GD; Curtin JF; Candolfi M; Xiong W; Liu C; Puntel M; Cheng Q; Prieto J; Ribas A; Kupiec-Weglinski J; van Rooijen N; Lassmann H; Lowenstein PR; Castro MG Cancer Res; 2005 Aug; 65(16):7194-204. PubMed ID: 16103070 [TBL] [Abstract][Full Text] [Related]
12. Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. VanderVeen N; Paran C; Appelhans A; Krasinkiewicz J; Lemons R; Appelman H; Doherty R; Palmer D; Ng P; Lowenstein PR; Castro MG Mol Ther Methods Clin Dev; 2014 Feb; 1():10-. PubMed ID: 25068145 [TBL] [Abstract][Full Text] [Related]
13. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862 [TBL] [Abstract][Full Text] [Related]
14. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. VanderVeen N; Raja N; Yi E; Appelman H; Ng P; Palmer D; Zamler D; Dzaman M; Lowenstein PR; Castro MG Hum Gene Ther Methods; 2016 Jun; 27(3):98-111. PubMed ID: 27056322 [TBL] [Abstract][Full Text] [Related]
15. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. King GD; Muhammad AK; Xiong W; Kroeger KM; Puntel M; Larocque D; Palmer D; Ng P; Lowenstein PR; Castro MG J Virol; 2008 May; 82(9):4680-4. PubMed ID: 18287240 [TBL] [Abstract][Full Text] [Related]